#oncology
Latest news and interesting information about oncology.
Could GLP-1 drugs be oncology's next big opportunity?
New research suggests GLP-1 drugs may play a role in cancer prevention and treatment, opening a potential new frontier for these popular therapies.
Immunome presents phase 3 trial results for desmoid tumor drug
Immunome announces phase 3 results for varegacestat in desmoid tumors: 84% reduction in progression risk, 56% objective response rate.
Barclays Starts Oncology Biotechs with Positive Outlook
Barclays initiates coverage of Alpha Tau Medical, Cellectis, Immunome, and Sutro Biopharma with Overweight ratings.
Hutchmed stock hits 52-week low at 11.7 USD
Hutchmed stock hits 52-week low at $11.70. P/E 4.64, fair value $14.06. Strong oncology earnings from HUTCHMED.
Kura Oncology SWOT Analysis: Launch Test
Kura Oncology SWOT analysis: FDA approval, early sales results, and future prospects for this biotech stock.
Pfizer SWOT analysis: new drugs
Pfizer SWOT analysis: new drugs Tukysa and anti-obesity strategy to navigate patent cliff.
Why is Merck stock surging today?
Merck stock surges 4.7% on positive lung cancer trial results, strong Q1 earnings, and EMA recommendation for Keytruda combination in bladder cancer.
Kura Oncology SWOT: Biotech Stock Faces Launch Test
Kura Oncology SWOT analysis: Komzifti launch, financials, analyst ratings, and investment risks covered in detail.
VIR stock gains momentum on partnership and clinical progress
SWOT analysis of Vir Biotechnology: Astellas partnership, VIR-5500 and Hepatitis Delta program progress boost stock. Read on Bond.az.
Immuneering stock jumps on pancreatic cancer trial data
Immuneering stock jumps 12.5% after promising pancreatic cancer trial results.
Revolution Medicines Phase 3 Results Webcast
Revolution Medicines webcast on Phase 3 RASolute 302 results for daraxonrasib in pancreatic cancer. Learn more.
Koru Medical CTO Buys $19,562 in Stock
Koru Medical CTO Eric Schiller buys $19,562 in stock. KRMD price at $4.00, down 32% YTD.
Biotech at Inflection Point: JPMorgan Covers 14 Firms | Bond.az
JPMorgan covers 14 biotech firms at inflection point, with ratings and price targets. See which companies are poised for growth and the catalysts ahead.
H.C. Wainwright reiterates MindWalk stock rating on platform validation
H.C. Wainwright reiterates Buy rating and $5 target on MindWalk stock, citing platform validation and strong pipeline. Read more.
Avacta reports 2025 results, raises £32.5m for oncology trials
Avacta Group reports 2025 preliminary results, raises £32.5 million for oncology trials. Updates on AVA6103 and AVA6000 programs.
Genentech to Present Breast Cancer Data at ASCO Meeting
Genentech will present breast cancer data on giredestrant and other drugs at the 2026 ASCO meeting.
Revolution stock buy rating from Truist
Truist Securities gives Revolution Medicines a buy rating with a $179 price target. Daraxon's potential and company outlook.
Sumitomo Pharma Q4 2025 Beats EPS Forecasts
Sumitomo Pharma Q4 2025 earnings beat EPS forecasts. The company achieved record profitability in FY 2025, driven by strong U.S. sales of ORGOVYX and GEMTESA.
Truist raises CG Oncology target to $82 on NMIBC data
Truist Securities raises CG Oncology price target to $82 from $77 on NMIBC data. Stock near 52-week high after 206% yearly gain.
...